Today: 30 April 2026
Browse Category

NASDAQ:RYTM 11 December 2025 - 30 December 2025

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
30 December 2025
··
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals shares jumped over 15% to a record high near $121 on December 11 after reporting positive interim Phase 2 data for setmelanotide in Prader-Willi syndrome. Six of eight patients showed BMI reductions at three months, and most saw declines in hunger scores. The company plans a Phase 3 trial pending Phase 2 completion. RYTM stock is up around 80–90% year-to-date.
11 December 2025
·

Stock Market Today

  • Morgan Stanley Launches First Major Wall Street Spot Bitcoin ETF
    April 30, 2026, 11:57 AM EDT. Morgan Stanley debuted MSBT, its spot Bitcoin exchange-traded fund (ETF), marking the first from a major Wall Street bank. The ETF charges a 0.14% fee aimed at attracting institutional investors. Despite this, markets remain cautious; Bitcoin reaching $80,000 in April dropped from 26% to 17% YES on prediction markets the same day. This decline signals skepticism that the ETF alone will drive significant short-term price gains. Year-end Bitcoin price optimism remains modest at 5% YES, hampered by thin liquidity and broader concerns like regulatory and geopolitical challenges. Monitoring inflows into MSBT and rivals like BlackRock's IBIT will be crucial to gauge real institutional interest.

Latest article

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

30 April 2026
A retiree’s claim that Social Security payroll taxes could have grown to $4 million in the S&P 500 has renewed debate over the system’s structure. The Social Security Administration projects its main trust fund will be depleted by 2033, with incoming revenue covering 77% of benefits. The fund invests only in government securities, not stocks. The payroll tax rate is set at 12.4% of earnings up to $184,500 in 2026.
Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

30 April 2026
FatPipe shares jumped 18% to $2.92 Thursday after the company announced expanded access to its SD-WAN and cybersecurity products through public-sector procurement channels. The move follows a VeloCloud replacement program targeting customers of Arista Networks’ SD-WAN business. Trading volume reached 42.2 million shares. Investors remain cautious over execution and customer concentration risks.
Go toTop